The Division of Neurodevelopmental-Behavioral Pediatrics provides diagnosis and clinical care for infants and children who have, or who are at risk for, developmental conditions.
Our faculty see patients at the following Waisman Center clinics: Autism and Developmental Disabilities Clinic, Newborn Follow-Up Clinic, Feeding Team, Down Syndrome Clinic, and the Neuromotor Development Clinic. They also see patients at the UW Health East Clinic.
Division faculty also provide education on neurodevelopmental disabilities through invited presentations, postgraduate programs at UW-Madison and rotations for second-year pediatric residents and neonatal fellows.
- The division welcomed a new faculty member, Kathleen Kastner, MD.
- Janet Legare, MD, presented at regional and national Little People of America conferences.
- The Newborn Follow-Up clinic continued to expand, with an increased role for neonatology fellows. The Down Syndrome clinic also expanded to meet increasing demands for care.
- Division members created online lectures and enduring materials for the UW School of Medicine and Public Health’s medical student curriculum. Dr. Kastner also developed a new elective rotation for medical students.
- Division members participated in planning and joined clinician panels for the Waisman Center Days with the Experts.
Clinical Associate Professor and Division Chief
Associate Professor (CHS)
Assistant Professor (CHS)
Clinical Associate Professor
Legare JM, Seaborg K, Laffin J, Giampietro PF. Diaphanospondylodysostosis and ischiospinal dysostosis, evidence for one disorder with variable expression in a patient who has survived to age 9 years. Am J Med Genet A. 2017 Oct;173(10):2808-2813. doi: 10.1002/ajmg.a.38395. Epub 2017 Aug 17. PubMed PMID: 28815954.
Our faculty were principal investigators and/or co-investigators on the following grants during calendar year 2017.
|Stanley, Maria A (PI)||Genentech, Inc.||BP27832 Treatment Protocol|
|Stanley, Maria A (PI)||Roche||A randomized, double-blind, placebo-controlled, parallel group 26-week dose-investigating study to explore the pharmacokinetics, pharmacodynamic effects, efficacy, safety and tolerability of RO5186582 in children with Down Syndrome aged 6-11 years|
|Stanley, Maria (co-I) with Durkin, Maureen (PI)||DHHS, PHS, Centers for Disease Control & Prevention||Wisconsin study to explore early development of autism (SEED)|